13049-01-9

Usage

Uses

Used in Organic Synthesis:
GLYCINE N-PROPYL ESTER HYDROCHLORIDE is used as a reactant or reagent for its versatility in various chemical reactions, facilitating the synthesis of a range of organic compounds.
Used in Medicinal Chemistry:
GLYCINE N-PROPYL ESTER HYDROCHLORIDE is used as a key component in the development of pharmaceuticals, contributing to the creation of new drugs and therapeutic agents.
Used in Pharmaceutical Production:
GLYCINE N-PROPYL ESTER HYDROCHLORIDE is used as a reactant in the production of pharmaceuticals, playing a crucial role in the synthesis of active pharmaceutical ingredients.
Used in Agrochemical Production:
GLYCINE N-PROPYL ESTER HYDROCHLORIDE is used as a reactant in the synthesis of agrochemicals, aiding in the development of effective crop protection agents.
Used as a Buffering Agent:
GLYCINE N-PROPYL ESTER HYDROCHLORIDE is used to stabilize pH levels in certain formulations, ensuring the stability and efficacy of various products.
Used in Research and Development:
GLYCINE N-PROPYL ESTER HYDROCHLORIDE is used in the pharmaceutical industry for research and development, exploring its potential pharmacological properties, including anti-inflammatory and analgesic effects.
Used in the Development of Drug Delivery Systems:
GLYCINE N-PROPYL ESTER HYDROCHLORIDE may be utilized in the design of drug delivery systems to improve the bioavailability and therapeutic outcomes of pharmaceuticals.

InChI:InChI=1/C5H11NO2/c1-2-3-8-5(7)4-6/h2-4,6H2,1H3

Upstream product

• 71-23-8 propan-1-ol 
• 6000-43-7 2-aminoethanoic acid hydrochloride 
• 56-40-6 glycine 

Downstream Products

• 81167-34-2 propyl 2-(diphenylmethyleneamino)acetate 
• 2979-59-1 propyl N-benzoyl-glycinate 
• 294177-64-3 propyl N-[3-phenyl-1-oxo-2-propen-1-yl] glycinate 

Relevant academic research and scientific papers

Synthesis and antimicrobial activities of novel sorbic and benzoic acid amide derivatives

A series of sorbic and benzoic acid amide derivatives were synthesized by conjugating sorbic acid (SAAD, a1–a7) or benzoic acid (BAAD b1–b6) with amino acid esters and their antimicrobial activities were investigated against Escherichia coli, Bacillus subtilis and Staphylococcus aureus, mixed bacteria from rancid milk, Saccharomyces cerevisiae, and Aspergillus niger. The antimicrobial activity of sorbic acid amides was better than that of benzoic acid amides. The minimum inhibitory concentrations (MIC) of compound isopropyl N-[1-oxo-2, 4-hexadien-1-yl]-L-phenylalaninate (a7) were 0.17 mM against B. subtilis, and 0.50 mM against S. aureus, while the MIC values of sorbic acid were more than 2 mM respectively. Also, compound a7 displayed pH-independent antimicrobial activity in the range of pH 5.0–9.0 and was effective at pH 9.0. These results demonstrated that the conjugation of sorbic acid with amino acid esters led to significant improvement of in vitro antimicrobial attributes, but little effect was observed for benzoic acid amide derivatives.

Antibacterial preservative is sorbic acid amino ester derivative and its preparation method

The invention belongs to the field of synthesis of a drug, and relates to a sorbic acid-amino acid ester derivate of an antimicrobial preservative and a preparation method thereof. The preparation method comprises the steps of: enabling amino acid and alcohol to react to generate amino-acid ester by utilizing an acyl chloride method, and then reacting with amino-acid ester by sorbic acid after acylating chlorination, so as to synthesize the amino acid ester derivate of the sorbic acid. The amino acid ester derivate of the novel compound sorbic acid obtained by the method has no sensitization on skin of a human body, is suitable for different pH systems with large ranges, has antibacterial broad-spectrum property and good potential application value, and can be used as the antimicrobial preservative applied to corrosion prevention and antibiosis of foods, drugs, cosmetics, pesticides, leather products and wood materials.

THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.